Emerging therapies in severe sepsis.
作者信息
Finney S J, Evans T W
机构信息
Imperial College School of Medicine, Royal Brompton Hospital, London SW3 6LY, UK.
出版信息
Thorax. 2002 Oct;57 Suppl 2(Suppl 2):II8-II14.
Abstract
摘要
相似文献
1
Emerging therapies in severe sepsis.重症脓毒症的新兴疗法
Thorax. 2002 Oct;57 Suppl 2(Suppl 2):II8-II14.
2
Continuing challenges of sepsis research.脓毒症研究面临的持续挑战。
JAMA. 2001 Oct 17;286(15):1894-6. doi: 10.1001/jama.286.15.1894.
3
4
[Studies on low protein C-expression in severe sepsis].[严重脓毒症中低蛋白C表达的研究]
Zentralbl Chir. 2005 Aug;130(4):362-7. doi: 10.1055/s-2005-836785.
5
Treatment of sepsis: what changed during the last decades?脓毒症的治疗：过去几十年间有哪些变化？
Acta Anaesthesiol Scand Suppl. 1997;111:174-6.
6
Sepsis: state of the art.脓毒症：最新进展
Dis Mon. 2001 Oct;47(10):465-532. doi: 10.1067/mda.2001.119745.
7
[Treatment of severe sepsis and septic shock].[严重脓毒症和脓毒性休克的治疗]
Presse Med. 2004 Feb 28;33(4):265-8; discussion 269. doi: 10.1016/s0755-4982(04)98553-3.
8
Best evidence in anesthetic practice: prevention: recombinant human activated protein C reduces mortality in severe sepsis.麻醉实践中的最佳证据：预防：重组人活化蛋白C可降低严重脓毒症的死亡率。
Can J Anaesth. 2002 Feb;49(2):207-9. doi: 10.1007/BF03020498.
9
Heparin: the cheap alternative for immunomodulation in sepsis?肝素：脓毒症免疫调节的廉价替代方案？
Crit Care Resusc. 2006 Sep;8(3):235-8.
10
[Protein C--a new opening in the treatment of sepsis syndrome].[蛋白C——脓毒症综合征治疗的新突破]
Duodecim. 2002;118(12):1217-9.
引用本文的文献
1
Employment Outcomes After Critical Illness: An Analysis of the Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors Cohort.危重症后的就业结局：对揭示ICU幸存者队列中神经心理功能障碍风险因素及发生率的分析
Crit Care Med. 2016 Nov;44(11):2003-2009. doi: 10.1097/CCM.0000000000001849.
本文引用的文献
1
Early goal-directed therapy in the treatment of severe sepsis and septic shock.早期目标导向治疗在严重脓毒症和脓毒性休克治疗中的应用
N Engl J Med. 2001 Nov 8;345(19):1368-77. doi: 10.1056/NEJMoa010307.
2
Intensive insulin therapy in critically ill patients.危重症患者的强化胰岛素治疗
N Engl J Med. 2001 Nov 8;345(19):1359-67. doi: 10.1056/NEJMoa011300.
3
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.重组人活化蛋白C用于严重脓毒症凝血病的安全性及剂量关系
Crit Care Med. 2001 Nov;29(11):2051-9. doi: 10.1097/00003246-200111000-00003.
4
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.重症患者的护理。严重脓毒症中高剂量抗凝血酶III：一项随机对照试验。
JAMA. 2001 Oct 17;286(15):1869-78. doi: 10.1001/jama.286.15.1869.
5
Dysfunction of endothelial protein C activation in severe meningococcal sepsis.严重脑膜炎球菌败血症中内皮细胞蛋白C激活功能障碍。
N Engl J Med. 2001 Aug 9;345(6):408-16. doi: 10.1056/NEJM200108093450603.
6
Tissue factor pathway inhibitor activity in severe sepsis.严重脓毒症中的组织因子途径抑制物活性
Crit Care Med. 2001 Jul;29(7 Suppl):S126-9. doi: 10.1097/00003246-200107001-00038.
7
Activated protein C versus protein C in severe sepsis.严重脓毒症中活化蛋白C与蛋白C的比较
Crit Care Med. 2001 Jul;29(7 Suppl):S69-74. doi: 10.1097/00003246-200107001-00024.
8
Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.重组人活化蛋白C：一种用于治疗严重脓毒症的血管功能系统调节剂。
Crit Care Med. 2001 Jul;29(7 Suppl):S53-60; discussion S60-1. doi: 10.1097/00003246-200107001-00020.
9
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.美国严重脓毒症的流行病学：发病率、转归及相关护理费用分析
Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002.
10
New strategies for clinical trials in patients with sepsis and septic shock.脓毒症和脓毒性休克患者临床试验的新策略。
Crit Care Med. 2001 Apr;29(4):880-6. doi: 10.1097/00003246-200104000-00039.
Zotero 插件